# AstraZeneca tozorakimab COPD clinical trials > Live situation record from CLSTR: https://clstr.news/situations/astrazeneca-tozorakimab-copd-clinical-trials > Updated: 2026-09-11T15:21:00.000Z. Sources: 16. Developments: 2. AstraZeneca has reported positive results from two Phase 3 clinical trials, OBERON and TITANIA, regarding its experimental monoclonal antibody, tozorakimab, for the treatment of chronic obstructive pulmonary disease (COPD). The drug targets interleukin-33 (IL-33) to block inflammatory processes. Trial data indicates that tozorakimab reduces moderate to severe exacerbations by approximately 29% to 34% among former smokers and roughly 29% to 30% in the broader population of current and former smokers. The treatment appears effective regardless of blood eosinophil levels, with exacerbation reductions exceeding 40% for patients with eosinophil counts of 300 or higher and between 20% and 30% for those with lower counts. The drug was reported to be generally well-tolerated, with injection-site reactions being the primary adverse effect. The U.S. Food and Drug Administration (FDA) has accepted tozorakimab for priority review as an add-on maintenance therapy for adults with COPD. AstraZeneca is also exploring the drug’s potential use for asthma and bronchiectasis. ## Timeline ### 2026-09-11: AstraZeneca reports 30% reduction in COPD exacerbations with tozorakimab AstraZeneca's Phase III trials for tozorakimab show the biologic drug reduces COPD exacerbations by 30%, demonstrating efficacy regardless of a patient's blood eosinophil levels. 6 sources. https://clstr.news/cluster/astrazeneca-reports-30-reduction-in-copd-exacerbations-with-tozorakimab ### 2026-09-08: AstraZeneca drug tozorakimab reduces COPD exacerbations in Phase 3 trials AstraZeneca's experimental drug tozorakimab has shown a significant reduction in moderate to severe COPD exacerbations in Phase 3 trials, regardless of a patient's smoking status or eosinophil levels. 10 sources. https://clstr.news/cluster/astrazeneca-drug-tozorakimab-reduces-copd-exacerbations-in-phase-3-trials --- Cite as: AstraZeneca tozorakimab COPD clinical trials. CLSTR, https://clstr.news/situations/astrazeneca-tozorakimab-copd-clinical-trials